Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes drug takes on childhood cancers in early safety trial

NCT ID NCT05521984

Recruiting now Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether dapagliflozin, a diabetes medicine, is safe for children with brain or solid tumors that have come back or not responded to other treatments. About 20 children will receive the drug alongside standard care. The goal is to check for side effects, not to cure the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEDIATRIC BRAIN TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

childhood neoplasm neuroblastoma primary brain neoplasm refractory malignant neoplasm sarcoma Wilms tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PEDIATRIC BRAIN TUMOR PEDIATRIC SOLID TUMOR

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Washington University School of Medicine/St. Louis Children's Hospital

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.